Endologix Inc. Receives IDE Approval for the Ventana(TM) Fenestrated Stent Graft System
9/6/2011 10:13:39 AM
IRVINE, Calif., Sept. 6, 2011 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that it has received Investigational Device Exemption ("IDE") conditional approval from the United States Food and Drug Administration ("FDA") to begin U.S. clinical trials to evaluate the Ventana™ Fenestrated Stent Graft System for the endovascular repair of juxtarenal and pararenal aortic aneurysms. Endologix expects to begin enrolling patients at a few centers in the U.S. before the end of this year.
comments powered by